Randomized phase II study of docetaxel vs Paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy (OGSG1201)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus platinum (OGSG0701)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP（OGSG0701）

Five-year outcome of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy (OGSG0604)

A randomized phase II factorial design trial of CPT-11 versus PTX versus each combination with S-1 in patients with advanced gastric cancer refractory to S-1: Final results of OGSG0701

A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:（OGSG1001）

Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002)

StageIII胃癌を対象とした術後補助化学療法としてのDocetaxel + S1併用療法の第2相臨床試験(OGSG0604)

StageⅢ 胃癌に対するdocetaxel+S-1 術後補助化学療法(3 か月投与) の第2 相試験 (OGSG0604)

病期IIIA/B 胃癌患者を対象としたドセタキセル+TS1 併用術後補助化学療法の第二相試験(OGSG0604) の予後解析